Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 5

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1Other solid neoplasm 1Gynecologic 1

Conditions

Breast Neoplasms 2Solid Tumor 1Neoplasms 1Neoplasm Metastasis 1Endometrial Neoplasms 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × trastuzumab duocarmazine × Clear all
NCT04205630 2024-05-30

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Byondis B.V.

Phase 2 Completed
64 enrolled 13 charts
Gynecologic

Endometrial Neoplasms

NCT04235101 2024-01-05

Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors

Byondis B.V.

Phase 1 Completed
32 enrolled
Other solid neoplasm

Solid Tumor

NCT04983238 2024-01-05

Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985

Byondis B.V.

Phase 1/2 Completed
48 enrolled
Breast

Breast Neoplasms

NCT03262935 2023-10-19

TULIP

Byondis B.V.

Phase 3 Completed
437 enrolled 17 charts
Breast

Breast Neoplasms

NCT02277717 2023-08-14

First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients

Byondis B.V.

Phase 1 Completed
185 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡